Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

BPC-157 is debated for hair loss, with some claiming it helps, but most agree there's no solid evidence for hair regrowth. Finasteride is mentioned as a common treatment, but results vary.

People are using various treatments for hair loss, including minoxidil, finasteride, dutasteride, tretinoin, and RU58841. Some are experimenting with additional compounds like GhK-cu and are interested in future treatments like extended-release oral minoxidil.

Pattern hair loss before age 35 may be linked to higher risks of prostate cancer, cardiovascular diseases, and metabolic syndrome later in life. Finasteride is discussed as a treatment that may lower PSA levels and potentially prevent prostate issues.

The conversation discusses enhancing a 1% topical finasteride solution for hair retention and regrowth with additional ingredients like melatonin, caffeine, and adenosine, while considering stability and efficacy. Concerns are raised about the stability of topical finasteride, with suggestions to use oral finasteride or obtain fresh formulations from a trusted pharmacy.

The user is experiencing significant hair shedding despite using 1.25mg oral minoxidil and 1mg finasteride daily for a year. They are advised to monitor health factors like vitamin levels and heart health, and consider increasing ferritin levels for optimal hair growth.

PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.

Gut microbiome imbalances can cause scalp inflammation and affect hair follicles, potentially leading to hair loss. Treatments include finasteride, peptides like BPC-157, TB-500, KPV, and lifestyle changes such as diet and exercise.

A permanent hair loss solution could involve reprogramming hair follicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.

Shorter microneedle lengths, like 0.5mm, may be more effective and safer for hair regrowth than longer ones, such as 1.5mm, which can cause more pain and risk. Users report success with various regimens, including minoxidil, finasteride, and other topicals, alongside microneedling.

The conversation humorously discusses using anal administration of Dutasteride as a novel method for treating hair loss, suggesting it could target DHT production more effectively. It includes satirical comments about the method's potential effects and absurd outcomes.

An 18-year-old male using topical finasteride and minoxidil for hair loss is considering adding oral finasteride. Users advise against combining both forms of finasteride due to increased side effects and suggest switching to oral finasteride or dutasteride for better results, noting that finasteride is less effective on hairlines.

Doctors recommend starting with minoxidil for hair loss due to its lower risk of side effects compared to finasteride. Some believe finasteride should be used early to address the root cause, but a conservative approach is preferred by medical professionals.

The user started using 5% liquid minoxidil on their scalp and noticed increased facial dryness and faster facial hair growth. They plan to reduce the application to once a day to see if it helps with the dryness.

The user switched from oral minoxidil to topical minoxidil and added JXL-069/PP405-3HP, along with topical dutasteride, melatonin, and tretinoin. They also use low-level laser therapy (LLLT) but doubt its effectiveness.

L. reuteri, a probiotic, is being explored for its potential benefits in treating androgenic alopecia, possibly enhancing finasteride's effects and reducing inflammation. The user combines this with finasteride, oral minoxidil, and other supplements, noting some improvement in hair loss.

The user is experiencing hair thinning and is using minoxidil, dutasteride injections, and red light therapy with little success after 4.5 months. Suggestions include switching to finasteride instead of dutasteride injections.

Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.

The conversation discusses the safety and use of ketoconazole shampoo for hair loss, with mentions of zinc pyrithione and selenium sulfide. Users debate the safety of these ingredients, particularly zinc pyrithione, and share opinions on regulatory differences between Europe and the US.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

A 23-year-old is using 2.5 mg dutasteride, 5 mg oral minoxidil, RU58841, a laser cap, and PRF injections for hair loss. They are hesitant about microneedling due to concerns about RU58841 absorption and are considering other treatments.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

Finasteride and Dutasteride do not cause depression or mood disorders; hair loss itself may be a more significant factor. Some users experience side effects from Finasteride, but it is generally well-tolerated.

Topical dutasteride is more effective than finasteride for hair loss but lacks FDA approval and research, leading to less use. Users report varying effectiveness and side effects, with some preferring oral treatments.

The user saw significant hair regrowth using topical minoxidil and finasteride, even on areas not directly treated. They used local Algerian products with 5% minoxidil and 0.1% finasteride and reported no side effects.

The user reported subtle hair regrowth by focusing on scalp health and lifestyle changes, using Nizoral shampoo and methods to reduce inflammation and cortisol, without using finasteride, minoxidil, or other common treatments. Opinions in the conversation varied, with some skeptical of the results and others acknowledging the potential benefits of addressing scalp health and inflammation.

Topical finasteride with minoxidil effectively stabilized and thickened hair but caused side effects like brain fog, reduced libido, and emotional flattening, leading to discontinuation. The user switched to a new regimen including minoxidil, KX-826, and other treatments, noting improvements in libido and vivid dreams after stopping finasteride.

A new hair loss protocol using FDA-approved topical treatments targets eight pathways, potentially improving results by 60-75% compared to the standard 40-50% from oral minoxidil and finasteride. The protocol includes minoxidil, finasteride, tacrolimus, cetirizine, bimatoprost, lithium gluconate, losartan, melatonin, NAC, caffeine, and tretinoin, with a monthly cost of $35-50 in Mexico and $80-150 in the US.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

Microneedling should be done every 1-2 weeks, with a recommended wait of at least 24 hours before applying topical minoxidil. Finasteride is planned to be used daily at 1mg.

Reducing the dose of RU58841 from 25mg to 7.5mg topically helped minimize heart palpitations. Users discussed the cardiac effects of RU58841 and minoxidil, noting that no treatment is completely free of side effects.